KIT positive
|
GIST
|
KIT positive
|
GIST
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
PDGFRA D842V
|
GIST
|
PDGFRA D842V
|
GIST
|
avapritinib Sensitive: A1 - Approval
|
avapritinib Sensitive: A1 - Approval
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
sunitinib Sensitive: A1 - Approval
|
sunitinib Sensitive: A1 - Approval
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
ripretinib Sensitive: A1 - Approval
|
ripretinib Sensitive: A1 - Approval
|
PDGFRA exon 18 mutation
|
GIST
|
PDGFRA exon 18 mutation
|
GIST
|
avapritinib Sensitive: A1 - Approval
|
avapritinib Sensitive: A1 - Approval
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
KIT expression
|
GIST
|
KIT expression
|
GIST
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
NTRK2 fusion
|
GIST
|
NTRK2 fusion
|
GIST
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
GIST
|
NTRK1 fusion
|
GIST
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
GIST
|
NTRK3 fusion
|
GIST
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
GIST
|
NTRK3 fusion
|
GIST
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GIST
|
NTRK2 fusion
|
GIST
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
GIST
|
NTRK1 fusion
|
GIST
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
cabozantinib tablet Sensitive: A2 - Guideline
|
cabozantinib tablet Sensitive: A2 - Guideline
|
PDGFRA exon 18 mutation
|
GIST
|
PDGFRA exon 18 mutation
|
GIST
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
PDGFRA D842V
|
GIST
|
PDGFRA D842V
|
GIST
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
pazopanib Sensitive: A2 - Guideline
|
pazopanib Sensitive: A2 - Guideline
|
No biomarker
|
GIST
|
No biomarker
|
GIST
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
TAS-116 Sensitive: B - Late Trials
|
TAS-116 Sensitive: B - Late Trials
|
KIT exon 17 mutation
|
GIST
|
KIT exon 17 mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT exon 13 mutation
|
GIST
|
KIT exon 13 mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT exon 17 mutation
|
GIST
|
KIT exon 17 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
KIT exon 13 mutation
|
GIST
|
KIT exon 13 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
KIT exon 18 mutation
|
GIST
|
KIT exon 18 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
KIT exon 14 mutation
|
GIST
|
KIT exon 14 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
ponatinib Sensitive: C2 – Inclusion Criteria
|
ponatinib Sensitive: C2 – Inclusion Criteria
|
PDGFRA D842V
|
GIST
|
PDGFRA D842V
|
GIST
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
sunitinib + PLX9486 Sensitive: C3 – Early Trials
|
sunitinib + PLX9486 Sensitive: C3 – Early Trials
|
KIT exon 11 mutation + KIT exon 17 mutation
|
GIST
|
KIT exon 11 mutation + KIT exon 17 mutation
|
GIST
|
nilotinib Sensitive: C3 – Early Trials
|
nilotinib Sensitive: C3 – Early Trials
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
TEKT4 mutation
|
GIST
|
TEKT4 mutation
|
GIST
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
SUFU mutation
|
GIST
|
SUFU mutation
|
GIST
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
SDHC mutation
|
GIST
|
SDHC mutation
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
TMEM127 mutation
|
GIST
|
TMEM127 mutation
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
SRC mutation
|
GIST
|
SRC mutation
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
GIST
|
TP53 mutation
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
APC mutation
|
GIST
|
APC mutation
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
KIT N822K
|
GIST
|
KIT N822K
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
KIT N820Y
|
GIST
|
KIT N820Y
|
GIST
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
KIT V560E
|
GIST
|
KIT V560E
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT V559_E561del
|
GIST
|
KIT V559_E561del
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT M552_V555delMYEV
|
GIST
|
KIT M552_V555delMYEV
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
PDGFRA I843_D846delIMHD
|
GIST
|
PDGFRA I843_D846delIMHD
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT W557_V559>F
|
GIST
|
KIT W557_V559>F
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT W557_V559>C
|
GIST
|
KIT W557_V559>C
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
PDGFRA D842V
|
GIST
|
PDGFRA D842V
|
GIST
|
sunitinib Resistant: C3 – Early Trials
|
sunitinib Resistant: C3 – Early Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
nilotinib Sensitive: C3 – Early Trials
|
nilotinib Sensitive: C3 – Early Trials
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
nilotinib Sensitive: C3 – Early Trials
|
nilotinib Sensitive: C3 – Early Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
PDGFRA D842V
|
GIST
|
PDGFRA D842V
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
CDK4 overexpression
|
GIST
|
CDK4 overexpression
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
TP53 overexpression
|
GIST
|
TP53 overexpression
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
MDM2 overexpression
|
GIST
|
MDM2 overexpression
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
DEPDC5 deletion
|
GIST
|
DEPDC5 deletion
|
GIST
|
imatinib + everolimus Sensitive: C3 – Early Trials
|
imatinib + everolimus Sensitive: C3 – Early Trials
|
KIT exon 11 W557_K558delins
|
GIST
|
KIT exon 11 W557_K558delins
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
SDHB mutation
|
GIST
|
SDHB mutation
|
GIST
|
temozolomide Sensitive: C3 – Early Trials
|
temozolomide Sensitive: C3 – Early Trials
|
KIT V654A
|
GIST
|
KIT V654A
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT Y823D
|
GIST
|
KIT Y823D
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT N822Y
|
GIST
|
KIT N822Y
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT D820A
|
GIST
|
KIT D820A
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT D820G
|
GIST
|
KIT D820G
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT N822K
|
GIST
|
KIT N822K
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT D820Y
|
GIST
|
KIT D820Y
|
GIST
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT exon 17 mutation
|
GIST
|
KIT exon 17 mutation
|
GIST
|
avapritinib Resistant: C4 – Case Studies
|
avapritinib Resistant: C4 – Case Studies
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
avapritinib Resistant: C4 – Case Studies
|
avapritinib Resistant: C4 – Case Studies
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
avapritinib Resistant: C4 – Case Studies
|
avapritinib Resistant: C4 – Case Studies
|
BRAF V600E
|
GIST
|
BRAF V600E
|
GIST
|
sorafenib Resistant: C4 – Case Studies
|
sorafenib Resistant: C4 – Case Studies
|
KIT positive + CD34 positive + ANO1 positive + ACTA2 positive
|
GIST
|
KIT positive + CD34 positive + ANO1 positive + ACTA2 positive
|
GIST
|
imatinib Sensitive: C4 – Case Studies
|
imatinib Sensitive: C4 – Case Studies
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
AZD1775 Sensitive: D – Preclinical
|
AZD1775 Sensitive: D – Preclinical
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
GPR20 expression
|
GIST
|
GPR20 expression
|
GIST
|
DS-6157 Sensitive: D – Preclinical
|
DS-6157 Sensitive: D – Preclinical
|
KIT exon 11 mutation + KIT exon 17 mutation
|
GIST
|
KIT exon 11 mutation + KIT exon 17 mutation
|
GIST
|
sunitinib + IPI 493 Sensitive: D – Preclinical
|
sunitinib + IPI 493 Sensitive: D – Preclinical
|
KIT exon 9 mutation
|
GIST
|
KIT exon 9 mutation
|
GIST
|
IPI 493 Sensitive: D – Preclinical
|
IPI 493 Sensitive: D – Preclinical
|
KIT P577del + KIT W557Lfs*5 + KIT Y823D
|
GIST
|
KIT P577del + KIT W557Lfs*5 + KIT Y823D
|
GIST
|
PM184 Sensitive: D – Preclinical
|
PM184 Sensitive: D – Preclinical
|
KIT P577del + KIT W557Lfs*5 + KIT Y823D
|
GIST
|
KIT P577del + KIT W557Lfs*5 + KIT Y823D
|
GIST
|
imatinib Resistant: D – Preclinical
|
imatinib Resistant: D – Preclinical
|
KIT W557_V559delinsF
|
GIST
|
KIT W557_V559delinsF
|
GIST
|
imatinib Sensitive: D – Preclinical
|
imatinib Sensitive: D – Preclinical
|
KIT W557_V559delinsF
|
GIST
|
KIT W557_V559delinsF
|
GIST
|
PM184 Sensitive: D – Preclinical
|
PM184 Sensitive: D – Preclinical
|